A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; KITE 718 (Primary)
- Indications Multiple myeloma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms HERMOSA-1
- Sponsors Gilead Sciences; Kite Pharma
- 23 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 22 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jul 2023.
- 11 May 2023 Planned End Date changed from 1 Apr 2023 to 1 May 2023.